Table 1 —

Demographics and baseline characteristics of subjects randomized and treated

Insulin glargineNPH insulin
n259259
M/F150 (57.9)/109 (42.1)161 (62.2)/98 (37.8)
Age (years)59.5 ± 9.759.2 ± 9.9
BMI (kg/m2)30.7 ± 5.030.4 ± 5.1
Race/ethnicity
 White208 (80.6)209 (80.7)
 Black40 (15.5)36 (13.9)
 Hispanic22 (8.5)22 (8.5)
Reported prior basal insulin schedule
 Once daily50 (19.3)50 (19.3)
 Twice daily205 (79.1)204 (78.7)
 More than twice daily4 (1.5)5 (1.9)
Prior regular insulin use161 (62.1)167 (64.4)
Diabetes history
 Duration (years)13.4 ± 8.314.1 ± 9.0
 Age at onset (years)46.7 ± 9.445.7 ± 10.7
 Insulin treatment (years)8.4 ± 6.98.3 ± 7.6
 C-peptide (mmol/l)0.6 ± 0.40.6 ± 0.5
History of retinopathy124 (47.9)147 (56.8)
Metabolic control
 HbA1c (%)8.6 ± 1.28.5 ± 1.2
 Fasting plasma glucose (mmol/l)10.6 ± 3.911.1 ± 4.3
 Fasting blood glucose (mmol/l)9.1 ± 2.49.2 ± 2.4
 Symptomatic hypoglycemia during screening phase66 (25.5)77 (29.7)
  • Data are n (%) or means ± SD.